QGEN vs. RVTY: Qiagen vs. Revvity Stock Comparison

November 11, 2026

How do Qiagen (QGEN) and Revvity (RVTY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Qiagen (QGEN) and Revvity (RVTY) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.

Company profile comparison for Qiagen (QGEN) and Revvity (RVTY)
Profile Item	QGEN	RVTY
Name	Qiagen N.V.	Revvity Inc.
Country/Region	Netherlands	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
GICS Sub-Industry	Life Sciences Tools & Services	Life Sciences Tools & Services
Market Capitalization	10.39 billion USD	17.31 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	June 28, 1996	February 21, 1973
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

QGEN

RVTY

GSPC

Qiagen (QGEN) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Qiagen (QGEN) and Revvity (RVTY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Qiagen (QGEN) and Revvity (RVTY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Total Return (1Y)	17.09%	76.75%
Total Return (3Y, Annualized)	10.44%	24.22%
Total Return (5Y, Annualized)	-0.72%	-1.48%

Risk Profile

Drawdown History

QGEN

RVTY

GSPC

Qiagen (QGEN) vs. Revvity (RVTY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Qiagen (QGEN) and Revvity (RVTY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Volatility (1Y, Annualized)	35.52%	40.22%
Beta (5Y)	0.56	1.07
Max Drawdown (5Y)	-41.97%	-59.01%
Avg. Volume (3M)	3.68M	1.89M

Risk-Adjusted Performance

Risk-Return Positioning

QGEN and RVTY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Sharpe Ratio (1Y)	0.36	1.80
Sortino Ratio (1Y)	0.60	2.90

Profitability

ROE (TTM)

Qiagen (QGEN) at 10.81% sits in the top ROE quartile, while Revvity (RVTY) at 3.45% is closer to the peer norm — stronger capital efficiency for QGEN.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.81%

Max: 109.18%
QGEN: 10.81%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.45%

Max: 109.18%
Q3: 6.23%
RVTY: 3.45%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Qiagen (QGEN) at 18.20% keeps the most of each sales dollar — above its industry’s net margin range — and Revvity (RVTY) at 8.61% also retains a top-quartile share.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.20%

QGEN: 18.20%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

8.61%

Max: 18.05%
RVTY: 8.61%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Qiagen (QGEN) at 27.75% and Revvity (RVTY) at 17.06% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.75%

Max: 83.12%
QGEN: 27.75%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

17.06%

Max: 83.12%
RVTY: 17.06%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
ROE (TTM)	10.81%	3.45%
ROA (TTM)	5.68%	2.54%
Net Margin (TTM)	18.20%	8.61%
Operating Margin (TTM)	27.75%	17.06%
Gross Margin (TTM)	67.06%	55.91%

Growth

Revenue Growth

Both Qiagen (QGEN) at 5.65% and Revvity (RVTY) at 3.67% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Qiagen (QGEN) at 409.76% clears its industry range for EPS growth, a much stronger earnings trajectory than Revvity (RVTY) at -5.91%, which is closer to a typical peer reading.

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Revenue Growth (YoY)	5.65%	3.67%
Revenue Growth (3Y CAGR)	-0.81%	-4.82%
EPS Growth (YoY)	409.76%	-5.91%
EPS Growth (3Y CAGR)	-0.19%	-23.26%

Financial Strength

Current Ratio (MRQ)

Both Qiagen (QGEN) at 2.63 and Revvity (RVTY) at 2.65 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.63

Max: 25.13
Q3: 12.13
Median: 5.52
QGEN: 2.63
Q1: 2.47
Min: 0.10

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.65

Max: 25.13
Q3: 12.13
Median: 5.52
RVTY: 2.65
Q1: 2.47
Min: 0.10

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Qiagen (QGEN) at 0.47 and Revvity (RVTY) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.47

Max: 1.42
Q3: 0.65
QGEN: 0.47
Median: 0.15
Q1: 0.02
Min: 0.00

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
RVTY: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Current Ratio (MRQ)	2.63	2.65
Debt / Equity (MRQ)	0.47	0.38
Net Debt / EBITDA	1.08	2.43

Dividends

Dividend Yield (TTM)

Both Qiagen (QGEN) at 0.71% and Revvity (RVTY) at 0.19% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.71%

QGEN: 0.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.19%

RVTY: 0.19%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Qiagen (QGEN) at 18.21% and Revvity (RVTY) at 13.40% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

18.21%

QGEN: 18.21%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.40%

RVTY: 13.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
Dividend Yield (TTM)	0.71%	0.19%
Dividend Payout Ratio (TTM)	18.21%	13.40%

Valuation

P/E Ratio (TTM)

Qiagen (QGEN) at 27.21 is near its industry’s usual P/E ratio, while Revvity (RVTY) at 68.94 sits in the richer quartile — RVTY needs stronger growth or earnings quality to justify the premium.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

27.21

Max: 85.34
Q3: 43.46
QGEN: 27.21
Median: 26.69
Q1: 13.30
Min: 0.07

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

68.94

Max: 85.34
RVTY: 68.94
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Qiagen (QGEN) at 4.91 and Revvity (RVTY) at 5.88 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.91

Max: 58.18
Q3: 25.77
Median: 7.30
QGEN: 4.91
Q1: 3.01
Min: 0.01

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.88

Max: 58.18
Q3: 25.77
Median: 7.30
RVTY: 5.88
Q1: 3.01
Min: 0.01

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

On P/B ratio, both Qiagen (QGEN) at 2.99 and Revvity (RVTY) at 2.39 are valued close to their industries’ norm against book — neither stands out from peers.

QGEN

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.99

Max: 13.53
Q3: 6.54
Median: 3.25
QGEN: 2.99
Q1: 1.69
Min: -5.59

RVTY

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.39

Max: 13.53
Q3: 6.54
Median: 3.25
RVTY: 2.39
Q1: 1.69
Min: -5.59

Qiagen (QGEN) vs. Revvity (RVTY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Qiagen (QGEN) and Revvity (RVTY)
Metric	QGEN	RVTY
P/E Ratio (TTM)	27.21	68.94
P/S Ratio (TTM)	4.91	5.88
P/B Ratio (MRQ)	2.99	2.39
Free Cash Flow Yield (TTM)	3.62%	3.62%